Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer

In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer patients have been evaluated in clinical trials. Apart from targeting extracellular receptors by the antibody aflibercept or the p...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Front Oncol
Hoofdauteurs: Mahner, Sven, Woelber, Linn, Mueller, Volkmar, Witzel, Isabell, Prieske, Katharina, Grimm, Donata, Keller-v Amsberg, Gunhild, Trillsch, Fabian
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2015
Onderwerpen:
Oncology
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4593253/
https://ncbi.nlm.nih.gov/pubmed/26500886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2015.00211
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items